ASCO 2019: Promising new data for patients with relapsed/refractory follicular lymphoma

Catherine S. Diefenbach | ASCO 2019 | Juni 5, 2019

Speaker: Catherine S. Diefenbach

In this MEDtalk Catherine Diefenbach presents a pre-planned interim analysis of the safety/efficacy of induction and maintenance with Polatuzumab vedotin (Pola) + obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma.